Illumina, Inc. · NASDAQ:ILMN
Illumina — Solexa — Merger or Acquisition (November 2006)
22 slides from Illumina's merger presentation, Nov 14, 2006
Slide 1: Creating A Powerful Life Science Franchise
Creating A Powerful Life Science Franchise 2006 Illumina (c), Inc. Illumina, Sentrix, Array of Arrays, BeadArray, DASL, Infinium, GoldenGate, iSelect, BeadXpress, VeraCode and Making Sense Out of Life are registered trademarks or trademarks of Illumina Inc. November 13, 2006
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Illumina, Inc. ("Illumina") and Solexa, Inc. ("Solexa") caution readers that any forward-looking information is not a guarantee of future performance and actual results could differ
Slide 3: Transaction Overview
Transaction Overview Offer Price: $14.00 per share Consideration: 100% Stock Collar: +7.5% Pro Forma Ownership: 79% Illumina; 21% Solexa Financing: Illumina has agreed to purchase $50M in newly issued Solexa stock at $9.70 per share Leadership: Jay Flatley, President & CEO John West, SVP & GM Sequen
Slide 4: A Strategically Compelling Opportunity
A Strategically Compelling Opportunity Whole genome and targeted resequencing are next high- growth markets in life sciences Genotyping and sequencing have natural synergy Digital gene expression will transform the expression market Solexa's "Best-of-Breed" platform primed for broad commercializatio
Slide 5: Combination Expands Target Markets by $1 Billion+
$1,250 $2,500 Combination Expands Target Markets by $1Billion+ $1 billion sequencing market today Sequencing incremental to genotyping business Market growth Genome centers poised for replacement cycle NCI cancer genome project Targeted resequencing Combined market >$2.25 billion today Total Market
Slide 6: Integration of Sequencing and Genotyping
Whole Genome Resequencing SNP discovery Rate mutation discovery Whole Genome Genotyping Disease associations 100,000's markers Focused Genotyping Fine mapping Validation 1,000's SNPs SNP Screening Validation 100's SNPs Biomarker discovery Diagnostic Genotyping Low-plex panels PGx Diagnostic Sequenci
Slide 7: Digital Gene Expression will Transform Market
Digital Gene Expression will Transform Market Solexa sequencing technology allows counting of number of expressed transcripts Counting transcripts yields quantitative comparison between samples and between genes within the same sample Digital data enables creation of databases that are fully compara
Slide 8: Distribution, Chemistry and Content Synergy
Industry leading genotyping platform Flexible, scalable array technology Targets research market Distribution, Chemistry and Content Synergy
Slide 9: Distribution, Chemistry and Content Synergy
Industry leading genotyping platform Flexible, scalable array technology Targets research market Launch next few months High sample throughput, low to mid multiplex Targets research and diagnostic market Shared Distribution Shared Chemistry Distribution, Chemistry and Content Synergy
Slide 10: Distribution, Chemistry and Content Synergy
Distribution, Chemistry and Content Synergy Shared Chemistry Shared Content Shared Distribution Industry leading genotyping platform Flexible, scalable array technology Targets research market Launch next few months High sample throughput, low to mid multiplex Targets research and diagnostic market
Slide 11: Delivers Broad, Novel Application Suite
Delivers Broad, Novel Application Suite ? Custom Assays ? Linkage V4 ? MHC Panel Human-1 HumanHap300 HumanHap240s HumanHap550 ? 96 Samples x 1400 Genes ? 16 Samples x 1400 Genes GoldenGate(r) (96, 384, 768, 1536 Multiplex) InfiniumTM (Unlimited Multiplexing) Whole Genome (Direct Hybridization) Focus
Slide 12: Solexa's Technology: The 1G Genome Analyzer
100x lower cost than today's standard Proprietary sequencing by synthesis chemistry Early access customer shipments underway Comprehensive IP portfolio Recent validation - Human X Chromosome Solexa's Technology The 1G Genome Analyzer
Slide 13: Solexa Technical Approach
Solexa Technical Approach DNA Clusters About 500 DNA copies per cluster Each about 1 micron in diameter Amplify DNA Sequencing Chemistry Extend by one base each step 4 fluorescent colors correspond to the 4 bases Computer-controlled Imaging tens of millions of clusters in parallel Solexa digital ima
Slide 14: Solexa 1G Genome Analyzer
Solexa 1G Genome Analyzer Solexa 1G Genome Analyzer
Slide 15: Key Technology Advantages
Key Technology Advantages Solexa Conventional Capillary Systems Basic operating scale Microscopic Macroscopic Sequences in parallel Up to 40 million 96 Instrument time per human genome < 1/2 machine year 50 machine years Consumables per human genome 60 chips Stack of 384-well plates 9x higher than E
Slide 16: Solexa Enhances Illumina's Management Team
John West Sr. VP & GM Sequencing Over 100 years of total management experience in science, technology, marketing and manufacturing 7 senior managers with direct experience launching leading sequencing platforms 2 independent directors from Solexa joining Illumina Board Solexa Enhances Illumina's Man
Slide 17: Combined Sales and Support Infrastructure Enables Rapid Commercialization
Combined Sales and Support Infrastructure Enables Rapid Commercialization 33 direct sales capable of selling 1G analyzer 58 Technical support staff capable of working with the 1G analyzer Distributors in Asia / parts of Europe 4 specialists focused on large genome centers
Slide 18: Takes Advantage of Illumina's Financial Strength
21 Consecutive Quarters of Revenue Growth Market Leading Margins - 30% in Q3 '06 Ending Q3 Cash balance $170M Takes Advantage of Illumina's Financial Strength
Slide 19: Financial Highlights
Financial Highlights Modestly accretive transaction in 2008 and significantly accretive thereafter Estimated to be 20 to 35% dilutive in 2007, excluding merger related charges Solexa enhances Illumina's trajectory Expanded commercialization of 1G Genome Analyzer in early 2007 VeraCode technology com
Slide 20: Clear Roadmap to Close
Clear Roadmap to Close Approval of Illumina and Solexa shareholders Customary regulatory approvals and other closing conditions Antitrust review under the Hart-Scott-Rodino Act Expected close by end of Q1 2007
Slide 21: Compelling Strategic Rationale
Compelling Strategic Rationale Combination creates the only company with leading technologies in genotyping, gene expression and sequencing Greatly expands market opportunity to over $2 billion Utilizes Illumina's world-class infrastructure, financial and technical resources to accelerate the commer
Slide 22: Slide 22